Glaucoma Subspecialty Day 2018

    This video discusses the 5-year Compass XT, the first prospective, randomized 5-year endothelial cell loss (ECL) data to be collected on any MIGS implant. Other MIGS or AC surgical approaches might be affected as well, and refractory glaucoma surgical approvals do not typically involve collection of 5-year safety data. The current data and action plan suggest that existing FDA and corporate long-term follow-up studies might be effective in ensuring patient safety after the approval of a MIGS device.